Adaptive Flagellin Polypeptide Solutions for Niche Environments

Publication ID: 24-11857614_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Flagellin Polypeptide Solutions for Niche Environments,” Published Technical Disclosure No. 24-11857614_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857614_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,614.

Summary of the Inventive Concept

The inventive concept adapts Enterococcus gallinarum flagellin polypeptides for specialized applications in high-security, disaster relief, extreme weather, and remote areas, enhancing immune response and disease treatment in these unique operational environments.

Background and Problem Solved

The original patent disclosed pharmaceutical compositions comprising Enterococcus flagellin polypeptides for general disease treatment. However, these compositions were not tailored for specific, high-stakes environments. This inventive concept addresses the limitations of the original patent by developing specialized solutions for niche markets, ensuring effective disease treatment and immune response in challenging conditions.

Detailed Description of the Inventive Concept

The inventive concept encompasses four primary variations: 1) a system for treating infectious diseases in remote or disaster-stricken areas, featuring a portable storage unit and disposable delivery device; 2) a method for enhancing immune response in individuals exposed to extreme weather conditions, utilizing a cryoprotectant; 3) a kit for high-security biodefense applications, incorporating a decontamination agent and portable diagnostic device; and 4) a composition for treating diseases in high-altitude or extreme-temperature environments, employing a thermally stabilized excipient. These adaptations ensure the effective use of Enterococcus gallinarum flagellin polypeptides in these unique environments.

Novelty and Inventive Step

The new claims introduce novel, non-obvious adaptations of the original Enterococcus gallinarum flagellin polypeptide compositions, specifically designed for high-security, disaster relief, extreme weather, and remote areas. These specialized solutions overcome the limitations of the original patent, providing a new level of effectiveness and reliability in these niche environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include integrating the flagellin polypeptide compositions with wearable devices, autonomous diagnostic systems, or advanced cryopreservation techniques to further enhance their utility in specialized applications.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the biodefense, disaster relief, and extreme environment industries, offering tailored solutions for high-stakes, niche markets. Potential applications include rapid disease diagnosis and treatment in emergency response situations, as well as enhanced immune response in individuals operating in extreme weather conditions.

CPC Classifications

SectionClassGroup
A A61 A61K39/09
A A61 A61K35/744
A A61 A61K2039/585
A A61 A61P37/04

Field of Art

Immunology, microbiology, and pharmaceutical compositions, specifically focusing on bacterial flagellin polypeptides and their therapeutic applications. Requires expertise in protein engineering, immunological response mechanisms, and pharmaceutical formulation techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in microbiology or immunology, experienced in protein characterization, drug delivery systems, and understanding bacterial protein interactions with immune systems. Familiar with techniques for modifying protein compositions for specialized environmental conditions

Obviousness Rationale

A person having ordinary skill would recognize that the source patent's Enterococcus gallinarum flagellin polypeptide provides a foundational composition that can be readily adapted for specialized environments using standard pharmaceutical engineering techniques. The PTD's variations represent predictable extensions of the original patent's core immunological technology, applying known formulation strategies to enhance utility in challenging operational contexts. These adaptations would be considered routine optimization within the skilled artisan's capabilities.

Obvious Combinations & Variations

Source Patent Element
Pharmaceutical composition with Enterococcus flagellin polypeptide designed to stimulate immune response
PTD Variation
Adding cryoprotectant for extreme weather immune enhancement
Obviousness Reasoning
Incorporating cryoprotectants is a standard technique in pharmaceutical formulations to preserve biological materials, representing a predictable solution for maintaining protein stability in variable environmental conditions
Source Patent Element
Enteric formulation of flagellin polypeptide
PTD Variation
Portable storage unit and disposable delivery device for remote area disease treatment
Obviousness Reasoning
Designing specialized delivery mechanisms for pharmaceutical compositions is a routine design choice for improving accessibility and administration in challenging environments
Source Patent Element
Pharmaceutical composition with specific sequence identity requirements
PTD Variation
Integrating portable diagnostic devices with flagellin polypeptide compositions
Obviousness Reasoning
Combining diagnostic technologies with immunological compositions is a known approach in medical research, representing an obvious extension of existing technological capabilities
Source Patent Element
Flagellin polypeptide from specific bacterial strain (Enterococcus gallinarum NCIMB 42488)
PTD Variation
Thermally stabilized excipient for high-altitude or extreme-temperature environments
Obviousness Reasoning
Developing thermal stabilization techniques for biological compositions is a standard pharmaceutical engineering practice, particularly for maintaining protein integrity in challenging environmental conditions
Source Patent Element
Immune response stimulation using flagellin polypeptide
PTD Variation
High-security biodefense kit with decontamination agent
Obviousness Reasoning
Adapting immunological compositions for specialized security applications represents a predictable technological progression using known formulation and integration strategies
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in the instant publication would have been obvious to a person having ordinary skill in the art at the time of invention, based on the teachings of US Patent 11857614. The proposed modifications represent routine optimization of the source patent's core technological concept, utilizing standard pharmaceutical engineering techniques to extend the flagellin polypeptide composition's utility across diverse operational environments.

Original Patent Information

Patent NumberUS 11,857,614
TitleEnterococcus gallinarum flagellin polypeptides
Assignee(s)CJ BIOSCIENCE, INC.